Table 1.
Patient clinical and epidemiological characteristics, N = 346
| Characteristic | N | (%) | Mean (std), range | |
|---|---|---|---|---|
| Age at Dx (years) | 59.7 (11.5), 25-93 | |||
| Gender | Male | 259 | 75 % | |
| Female | 87 | 25 % | ||
| Cancer Site | Larynx/Glottic | 83 | 24 % | |
| Oral Cavity | 126 | 36 % | ||
| Oropharynx | 125 | 36 % | ||
| Hypopharynx | 12 | 3 % | ||
| Cancer Stage | I/Cis | 47 | 14 % | |
| II | 35 | 10 % | ||
| III | 52 | 15 % | ||
| IV | 212 | 61 % | ||
| Comorbidities (ACE) | None | 91 | 26 % | |
| Mild | 158 | 46 % | ||
| Moderate | 70 | 20 % | ||
| Severe | 27 | 8 % | ||
| HPV status | Positive | 135 | 39 % | |
| Negative | 211 | 61 % | ||
| Tobacco Use | Current (within past 12 months) | 145 | 42 % | |
| Former (quit > 12 months) | 125 | 36 % | ||
| Never | 76 | 22 % | ||
| Pack Years, n = 257 | (cigs only) | 35.6 (30.0), 0.1-171.0 | ||
| Pack Years, n = 264 | (sum of cigs, cigars, pipe) | 37.7 (33.3), 0.07-242.9 | ||
| Alcohol Use, n = 244 | Never | 29 | 8 % | |
| Former (quit >12 months) | 227 | 66 % | ||
| Current (within past 12 months) | 90 | 26 % | ||
| Treatment, n = 335 | Surgery alone | 67 | 20 % | |
| Radiation alone | 34 | 10 % | ||
| Surgery + Radiation | 34 | 10 % | ||
| Radiation + Chemotherapy | 138 | 41 % | ||
| Surgery + Radiation + Chemotherapy | 39 | 12 % | ||
| No Treatment prior to death | 23 | 7 % | ||
| Persistent Diseasea | 29 | 8 % | ||
| Median Follow-up for Survival | 27 months | |||
| Median Follow-up for Recurrence/Persistence | 24 months | |||
| Recurrence/Persistenceb | 81 | |||
| Death | 78 | |||
| KM estimate 2 year RPFTc | 75 % | |||
| KM estimate 2 year OSTd | 79 % |
aDisease considered persistent if patient never became disease free. bRecurrence of the HNSCC in the primary, regional and/or a distant location. Persistent patients whose disease never cleared after treatment are included and considered recurrent with a recurrence time = 1 day. cRPFT Recurrence/Persistent Free Time defined as time from diagnosis to recurrence event or end of follow-up. End of follow-up is the last date where patient was reviewed for recurrence. Patients whose disease never cleared after treatment are considered recurrent with a recurrence time = 1 day. dOST Overall Survival Time. Death from any cause considered an event. Overall survival time defined from date of diagnosis by UM physician